Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.71 USD

96.71
526,084

-0.09 (-0.09%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $96.71 0.00 (0.00%) 6:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?

Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.

Sanghamitra Saha headshot

Use Rising P/E Strategy to Buy 5 Winning Stocks

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?

Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.

Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?

Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.

What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?

Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.

What's in Store for Boston Scientific's (BSX) Q2 Earnings?

We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.

Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?

NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.

Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.

Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.

Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR

Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR

Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sanghamitra Saha headshot

5 Top-Ranked Stocks Empowered by DuPont Analysis

Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Sumit Singh headshot

Bet on These 5 Stocks With Exciting Interest Coverage Ratio

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Amedisys (AMED) Upgraded to Strong Buy: Here's What You Should Know

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR

Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR

Top Ranked Momentum Stocks to Buy for June 21st

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 21st.

Sanghamitra Saha headshot

Bet Big on DuPont Analysis With These Top 5 Picks

Do you have more faith in DuPont analysis than a simple ROE calculation? Bet on these five stocks then.

Here is Why Growth Investors Should Buy Amedisys (AMED) Now

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos

Zacks.com featured highlights include: Intuit, Insperity, Amedisys, Pioneer Natural and Century Casinos

Sumit Singh headshot

5 Stocks With Impressive Interest Coverage Ratio to Buy Now

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR

Zacks.com featured highlights include: Shoe Carnival, Ulta, Amedisys, NVR and EMCOR

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Amedisys (AMED) Down 9.3% Since Last Earnings Report: Can It Rebound?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sanghamitra Saha headshot

Is Trade War Scaring You? Buy 5 DuPont-Tested Quality Stocks

Bet on five top-ranked stocks with higher ROE derived the DuPont way.